XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 08, 2020
USD ($)
Nov. 15, 2021
USD ($)
shares
Jan. 28, 2021
Dec. 31, 2020
USD ($)
$ / shares
shares
May 31, 2020
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Jul. 31, 2021
USD ($)
shares
Related Party Transactions (Details) [Line Items]                    
Related party expenses           $ 80,000 $ 90,000 $ 156,000 $ 155,000  
Due to related parties           $ 80,000 29,000 $ 80,000 29,000  
Area of land (in Square Meters) | m²           3,600   3,600    
Rent and parking expenses           $ 147,000 $ 460,000 $ 589,000 $ 867,000  
Related party receivables           $ 720,000   $ 720,000    
Services charges $ 3,000                  
Percentage of shares outstanding 5.00%                  
Payments to grant amount $ 120,000                  
Related party transaction, description The research period is over 13 months, with two additional 12-month options to extend.                  
Description of pharma holdings     On January 28, 2021, Pharma Holdings partially exercised the Warrant and purchased 7.3 million shares of Rafael Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings.               
Percentage of total revenue           63.00% 62.00% 57.00% 59.00%  
Acquired an additional membership interest       33.333% 33.333%          
Aggregate of a membership interest       66.666%            
RP finance LLC, description               The Company recognized approximately $0 and $96 thousand in earnings from its ownership interests of 37.5% in RP Finance for the three months ended January 31, 2022 and 2021, respectively, and a loss of $575 thousand and earnings of $192 thousand from its ownership interests of 37.5% in RP Finance for the six months ended January 31, 2022 and 2021, respectively. As of January 31, 2022, the equity method investment in RP Finance on the Company’s balance sheet was $0. The Company recorded a loss on related party receivables of $9.375 million related to amounts owed by RP Finance (see Note 5).     
Common stock for consideration               $ (6,228,000)    
Warrants percentage       20.00%            
Exercise price (in Dollars per share) | $ / shares       $ 22.91            
Ownership percentage   84.00%                
Securities Purchase Agreement [Member]                    
Related Party Transactions (Details) [Line Items]                    
Shares purchased (in Shares) | shares       218,245            
Common stock for consideration       $ 5,000,000            
IDT Rafael Holdings, LLC [Member]                    
Related Party Transactions (Details) [Line Items]                    
Rent and parking expenses               485,000 $ 8,000  
Rafael Pharmaceuticals [Member]                    
Related Party Transactions (Details) [Line Items]                    
Due from related parties           $ 0 $ 120,000 120,000 $ 240,000  
Due from owed amount           $ 720,000   $ 720,000   $ 600,000
Levco Pharmaceuticals Ltd [Member]                    
Related Party Transactions (Details) [Line Items]                    
Payments to grant amount $ 120,000                  
LipoMedix Pharmaceuticals, Ltd. [Member]                    
Related Party Transactions (Details) [Line Items]                    
Purchased shares (in Shares) | shares   15,975,000                
Due from owed amount   $ 3,000,000                
Outstanding loan balance   400,000                
Accrued interest   21,800                
Cash payment   $ 2,600,000                
Noncontrolling interest percentage   16.00%                
IDT Rafael Holdings, LLC [Member]                    
Related Party Transactions (Details) [Line Items]                    
Area of land (in Square Meters) | m²           80,000   80,000    
Common Class B [Member] | IDT Rafael Holdings, LLC [Member]                    
Related Party Transactions (Details) [Line Items]                    
Purchased shares (in Shares) | shares                   43,649
Shares issued (in Shares) | shares                   87,298
Common stock issued for proceeds                   $ 2,000,000